Meet Holly, Clear Cell Ovarian Cancer Survivor and Signatera Patient

September 2, 2025

Clear cell ovarian cancer can return—even years after treatment. #Signatera, Natera’s personalized MRD (ctDNA) test, looks for tiny traces of tumor DNA between scans and may detect molecular signs months before imaging, helping patients and care teams plan next steps sooner. Watch Holly’s story to see how MRD testing can support long-term follow-up. Learn more: https://www.natera.com/signaterapatients

Meet Holly, Clear Cell Ovarian Cancer Survivor and Signatera Patient

New data from ASCO 2025 & clinical performance of Natera’s ultra-sensitive MRD platform

ctDNA monitoring with Signatera: An overview for transplant providers

MRD in a minute: Marcus Noel, MD

MRD in a minute: Marcus Noel, md

MRD in a minute: Saum Ghodoussipour, MD

MRD in a minute: Saum Ghodoussipour, md

MRD in a minute: John Sfakianos, MD

MRD in a minute: John Sfakianos, md

MRD in a minute: Abstract overview Adanma Ayanambakkam, md

MRD in a minute: Abstract overview Adanma Ayanambakkam, MD

MRD in a minute: Caroline Koffke, bsn, rn

MRD in a minute: Caroline Koffke, BSN, RN

MRD in a minute: Signatera™ Genome

MRD in a minute: Signatera™ Genome CC

MRD in a minute: Changing how cancer is managed

MRD in a minute: Changing how cancer is managed

Tiny Traces, Big Impact: Changing the Paradigm in Breast Cancer Management with MRD Testing

ASBrS APP Course

ASBrS APP Course

ASBrS Symposia